Key facts
- It has raised $4.3M across 1 recorded rounds; the latest was Seed Round ($4.3M) in Sep 2022.
- Notable investors include Impact Assets, Bantam Group, HealthTech Capital, CH Innovations.
- Nurture Genomics has filed 3 Form Ds with the SEC since 2022, most recently Sep 2025 ($4.3M sold to 40 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nurture Genomics
Funding rounds
1 roundsAbout Nurture Genomics
Provider of genetic testing services intended for newborns and children. The company offers comprehensive genome sequencing that analyzes a broad range of genes associated with potential childhood-onset genetic conditions through a clinical care platform, enabling parents and pediatricians to get clear and actionable results and virtual consultations from genetic counselors.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 4
- Website
- nurturegenomics.com/
- Ownership
- Privately Held (backing)
Nurture Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nurture Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nurture Genomics in its N-PORT filings yet. We sweep new filings monthly.